Luis Vazquez Moyet, MD
Nephrology · Guayama, PRNPI 1831398429
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,158 of the $3,882 with a category attached, or 81.3%. 16 manufacturers reported payments, led by AstraZeneca at 26.2% of the total. Reporting peaked in 2019 at $1,211 and has fallen 72.0% since, to $340 in 2025.
Across 78 payments — averaging $49.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Fresenius USA Marketing, Inc.$901
- Johnson & Johnson$251
- Boehringer Ingelheim$230
- Bayer$190
- Calliditas Therapeutics US Inc.$185
- plus $1K from 10 others
What the payments were for
- Travel & lodging$71018%
- Food & beverage$3,15881%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $1,018 |
| Fresenius USA Marketing, Inc. | 4 | $901 |
| Johnson & Johnson | 4 | $251 |
| Boehringer Ingelheim | 5 | $230 |
| Bayer | 2 | $190 |
| Calliditas Therapeutics US Inc. | 2 | $185 |
| Bayer Puerto Rico Inc. | 8 | $173 |
| Amgen | 2 | $166 |
| Medtronic | 2 | $159 |
| Nxstage Medical, Inc. | 1 | $147 |
| Travere Therapeutics, Inc. | 1 | $124 |
| Otsuka America Pharmaceutical, Inc. | 1 | $119 |
| E.r. Squibb & Sons, L.L.C. | 1 | $100 |
| ANI Pharmaceuticals, Inc. | 4 | $87 |
| Chiesi USA, Inc. | 1 | $20 |
| PBG Puerto Rico LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$250
- LIBERTY SELECT CYCLER$147
- NXSTAGE SYSTEM ONE$147
- ELLIPSYS VASCULAR ACCESS SYSTEM$132
- JARDIANCE$125
- TARPEYO$125
- Kerendia$125
- Filspari$124
- XARELTO$119
- JYNARQUE$119
- Tavneos$117
How this compares
$3,882 in reported general payments places this provider in the 80th percentile of 161 nephrology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 303 | $196,852 |
| JardianceEmpagliflozin | 200 | $132,239 |
| KerendiaFinerenone | 114 | $78,692 |
| TradjentaLinagliptin | 127 | $68,216 |
| Sevelamer Carbonate | 266 | $33,046 |
| GlyxambiEmpagliflozin/Linagliptin | 32 | $20,481 |
| LokelmaSodium Zirconium Cyclosilicate | 25 | $16,397 |
| Lanthanum Carbonate | 26 | $12,085 |
| DapagliflozinDapagliflozin Propanediol | 11 | $4,368 |
| Allopurinol | 491 | $2,943 |
| Losartan Potassium | 344 | $2,581 |
| Hydralazine Hcl | 191 | $2,374 |
| Pioglitazone Hcl | 147 | $1,972 |
| Calcitriol | 81 | $1,798 |
| Calcium Acetate | 19 | $1,507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $230 | $220,936359 claims |
| AstraZenecaFarxiga, Lokelma | $1,018 | $213,249328 claims |
| BayerKerendia | $190 | $78,692114 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $87 | $96239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 161 nephrology providers in Puerto Rico.
Other nephrology in Guayama
- Eddie Rodriguez CastroToa Baja$591K
- William Hurtado-SantiagoMayaguez$191K
- William Vega OcasioCayey$40K
- Felix Perez RamosPonce$27K
- Antonio JimenezGuaynabo$16K
- Cesar Hernandez-ArroyoTrujillo Alto$13K
- Stephanie Colon-LopezBayamon$13K
- Pedro ColtonSanturce$12K
- Rafael Burgos CalderonBayamon$12K
- Angel Rivera SantosPonce$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.